Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Recurrent Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: Ruxolitinib|DRUG: Paclitaxel
Sponsor: Dana-Farber Cancer Institute
Collaborators: Incyte Corporation